Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

AIM: To compare the clinicopathological characteristics of human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative Barrett's adenocarcinoma in Japan. METHODS: We performed immunohistochemical analysis of HER2 in 30 samples taken from patients with Barrett's adenocarcinoma and dual color in situ hybridization in cases showing 2+ reactions. We compared the clinicopathological characteristics of HER2-positive and HER2-negative patients. RESULTS: HER2 positivity was identified in 8 (27%) carcinoma samples. We found that HER2 expression was associated with p53 overexpression (100% vs 52.6% in pT1 tumor; 100% vs 54.5% in all stage tumor, P <0.05) and protruding lesions at the early disease stage. There was no association between the mucin phenotype of the carcinomas and prognosis. HER2 expression and low clinical stage were unexpectedly different between Barrett's adenocarcinoma patients and gastric cancer patients, but the macroscopic features may be associated with earlier diagnosis in these patients. CONCLUSION: Our results suggest that HER2-positive Barrett's adenocarcinomas are associated with p53 overexpression and lesion protrusion at the early disease stage.

Original languageEnglish
Pages (from-to)6263-6268
Number of pages6
JournalWorld Journal of Gastroenterology
Volume18
Issue number43
DOIs
Publication statusPublished - 2012

Fingerprint

Adenocarcinoma
Carcinoma
human ERBB2 protein
Mucins
Stomach Neoplasms
In Situ Hybridization
Early Diagnosis
Neoplasms
Japan
Color
Phenotype

Keywords

  • Barrett's adenocarcinoma
  • Human epidermal growth factor receptor 2
  • Mucin phenotype
  • p53

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{0dffb8f499404bc6beb256d2f0c39ce4,
title = "Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma",
abstract = "AIM: To compare the clinicopathological characteristics of human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative Barrett's adenocarcinoma in Japan. METHODS: We performed immunohistochemical analysis of HER2 in 30 samples taken from patients with Barrett's adenocarcinoma and dual color in situ hybridization in cases showing 2+ reactions. We compared the clinicopathological characteristics of HER2-positive and HER2-negative patients. RESULTS: HER2 positivity was identified in 8 (27{\%}) carcinoma samples. We found that HER2 expression was associated with p53 overexpression (100{\%} vs 52.6{\%} in pT1 tumor; 100{\%} vs 54.5{\%} in all stage tumor, P <0.05) and protruding lesions at the early disease stage. There was no association between the mucin phenotype of the carcinomas and prognosis. HER2 expression and low clinical stage were unexpectedly different between Barrett's adenocarcinoma patients and gastric cancer patients, but the macroscopic features may be associated with earlier diagnosis in these patients. CONCLUSION: Our results suggest that HER2-positive Barrett's adenocarcinomas are associated with p53 overexpression and lesion protrusion at the early disease stage.",
keywords = "Barrett's adenocarcinoma, Human epidermal growth factor receptor 2, Mucin phenotype, p53",
author = "Takehiro Tanaka and Atsushi Fujimura and Koichi Ichimura and Hiroyuki Yanai and Yasuharu Sato and Katsuyohi Takata and Hiroyuki Okada and Seiji Kawano and Shunsuke Tanabe and Tadashi Yoshino",
year = "2012",
doi = "10.3748/wjg.v18.i43.6263",
language = "English",
volume = "18",
pages = "6263--6268",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "43",

}

TY - JOUR

T1 - Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma

AU - Tanaka, Takehiro

AU - Fujimura, Atsushi

AU - Ichimura, Koichi

AU - Yanai, Hiroyuki

AU - Sato, Yasuharu

AU - Takata, Katsuyohi

AU - Okada, Hiroyuki

AU - Kawano, Seiji

AU - Tanabe, Shunsuke

AU - Yoshino, Tadashi

PY - 2012

Y1 - 2012

N2 - AIM: To compare the clinicopathological characteristics of human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative Barrett's adenocarcinoma in Japan. METHODS: We performed immunohistochemical analysis of HER2 in 30 samples taken from patients with Barrett's adenocarcinoma and dual color in situ hybridization in cases showing 2+ reactions. We compared the clinicopathological characteristics of HER2-positive and HER2-negative patients. RESULTS: HER2 positivity was identified in 8 (27%) carcinoma samples. We found that HER2 expression was associated with p53 overexpression (100% vs 52.6% in pT1 tumor; 100% vs 54.5% in all stage tumor, P <0.05) and protruding lesions at the early disease stage. There was no association between the mucin phenotype of the carcinomas and prognosis. HER2 expression and low clinical stage were unexpectedly different between Barrett's adenocarcinoma patients and gastric cancer patients, but the macroscopic features may be associated with earlier diagnosis in these patients. CONCLUSION: Our results suggest that HER2-positive Barrett's adenocarcinomas are associated with p53 overexpression and lesion protrusion at the early disease stage.

AB - AIM: To compare the clinicopathological characteristics of human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative Barrett's adenocarcinoma in Japan. METHODS: We performed immunohistochemical analysis of HER2 in 30 samples taken from patients with Barrett's adenocarcinoma and dual color in situ hybridization in cases showing 2+ reactions. We compared the clinicopathological characteristics of HER2-positive and HER2-negative patients. RESULTS: HER2 positivity was identified in 8 (27%) carcinoma samples. We found that HER2 expression was associated with p53 overexpression (100% vs 52.6% in pT1 tumor; 100% vs 54.5% in all stage tumor, P <0.05) and protruding lesions at the early disease stage. There was no association between the mucin phenotype of the carcinomas and prognosis. HER2 expression and low clinical stage were unexpectedly different between Barrett's adenocarcinoma patients and gastric cancer patients, but the macroscopic features may be associated with earlier diagnosis in these patients. CONCLUSION: Our results suggest that HER2-positive Barrett's adenocarcinomas are associated with p53 overexpression and lesion protrusion at the early disease stage.

KW - Barrett's adenocarcinoma

KW - Human epidermal growth factor receptor 2

KW - Mucin phenotype

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=84873904185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873904185&partnerID=8YFLogxK

U2 - 10.3748/wjg.v18.i43.6263

DO - 10.3748/wjg.v18.i43.6263

M3 - Article

VL - 18

SP - 6263

EP - 6268

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 43

ER -